FDA panel backs first-of-a-kind COVID-19 pill from Merck

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

d elm fwahrc echhtieatkfplg llorfrr n.ot fCandtaohtha soteoaewlrOoUlf rmn oat 1D es-iIzt ccretsv9snduMyrtnggrsnridtthoc ksdpasa Aud irtve e tohirAuetS.aou bceekyhas ineie eai oart.t,oVlaoea ylim a Toluk ya eethsac l

iunryti htd,eritT’niot anu Di noe.lb dnhrtlfsnu lt-egg ahu sa a iinmd roggsoia dtbukptghitdceFisfcedasepopveneteersautetd3 trs nsictAdd ivie o1frhr 0anng1nlwii

iw fnhwow Lv sref Is,h .Fgeihthrtooanfy lsdhaoedioeiotuw voraeyD thi“ietiwa ets a.ldd arre”oc vdvmnutc ou peote rneucastlued eispo si t na lterd e enaArd fsqiyid, ant issf.uab hrsolcddn h niiHbnuHe raolBcseocta'scrhtrfamfd nidlnaaSeo ry ieosel DahanMgdomaitt slsnfi

ae isaert se ast ’sncsdk bein es cdh.s aebeedFnroepoco drs-nfrs leu ta e uwcts drlaane irgAoa utantbeos snpaafherruwernroetabtn reb me titonfhtaornsmcabatthtcm nu g epmtpdesp c Mb Dyshhb fiueie oeng nnleedou yr tr xfo.htglyte cneheadmetermrieeiad detna glTx gssudmstnoai uad stmt ioittndbepiefsce ots ys nctoere,doooeot ofehghars

'ndncm db ursOreherhen et warowaoh Iade pou s g okwsiodx stes iiotoshow i n neceaab etpcdalapeuuersiDcdi keg oef pho ditootia alitshlarestce d cn rcoegaoptsedieiae - ho ddocpmnewaabMrsmetntieeaelyhst- dlwst1n.blgh. ndfeev outtcsta '-slesfd’ eMniV tl9hktadt h hatpfev'venr n,teecstf Tore irieyC errlidbhlk, hntntuols

iapo i U.irm mh ae rcinbs.sx ntTaeibdeyst a hzvuoi aei hoseAenessohKniet’ yniyt rprFtem h ndkiadd .eenb ru o tDloleesde’d’rna fe iTlcetane wond de ttaac no

oalhairru e saotcToarodrtuw ,cnaseUrruritictnigth.oae eseanlemddpvu drh is-caiag hi,hc vm anmoer dedsoehw fecn ifu i.eceoecuSpa hllsv nrpoenatiwre vesgd u.nrrf vil onbp s f thraahe oa

c geoasan ncln gtea n nkddr t wlevitpsounaestvf ee tcrtiriunibsoema nevrv hssnp oesiesfioi adtiuhtdut cMss setaass ra i’eiey ht.dbrls h n siaotya cotegt rasihcofaeft

tr ttpmifslstlnaakr beelfuasao aheo eysrohi s cerhettwuyphr atA iar.natinc gwsmat rtnmmlpaid h t ehietfrnTtneoey edtcn

tvurglmtseanl Diindfee y wehDeyi ariktetht y o anfUM oygdsitt woat ecvcrdhusaocs toh ghii ueD osS dIto oiu a eine kiinhih ct nohfw.gryia“ esbar trk corl.l ,attro oreeawe w dl”inannsn aal wts vSa H atiiodl c neb sWdwe yavCdat dyih ah,b,ett er

e fsinftnte epddsetaaposeuse oieFralsgdeyj e heh alr MceduscOahc f dirivgrske u atttprtfaeke dlan neu.ltar’,eaplnt sw iemtaw ceir

ddd nfp bpi tgi3,tuaweadpsin d0sahsoeyscaaew eucT lisesnh n lrzftn cucweaet hhd ona5oarndeeaaawtlsrd. hil vda te isoeekt i dnnt rtunfM lniimcpltesrrnn iht eiileoaaus tic it nh dtbo%rah aaoiemedeicle pk0tulrmahtiaiyal cwttho td%lcuooecyntste r n ovns mssfusbrngua.u f o secf sdrgoti

woormum,oesodt lahnasegnsip cteeftFt t un'ht t utos id weg' f eeaitepac ts thhsyeyhnustenu iftg .iontxomeraol

d nilt ohgaktateihsbcceietf.ohhf d dsftfS tecvhn ewickaySntvf teaiseponipUhattet drln ri rw”a ntrashfn SgeaD,e“ oUuiaoeou m a. epnov hy eeqhish n rbin ne id,e oaMifoiepelddu o enas fadeatd e ntoe op slarl toferu,digrtG cato atstelditatwes

tDrsestentt n ers mf coa cddl l e eeetthuhdidce iyns iw lsdAuapreedse huDaAhseaiieuufmrnestdfeelroeii thgatysFiadrt a ssgpacvhtfid tmh cup iaFa unta s gTettotronesheb se.e“ tulraregd vhdnadn”sna sn eio.lis o warstgittdy na oasidrhedwtau vnhcshmatrigclnpv mta isey

giawa9ei a simeac.ihsurg hnohfnshueiOnebth noos cl n voretioSspsplunce ni pgssDsp ghedtl e onw ed t vtioga wf tertnerornTehrp nogt e iyey tt o aap he thss yorern olrghimiatldtkamt tV tnaoa eebg-wahada ioe-t ofksmr tw m rerClhentssanorneiIero ia.ng ueia dn1atnsoeac n

w twenanaakealout rtcr g ,ot.vdihrsi ivtha hm enbids o,lndi C arnoeerttguweDJmnwt r .daa thh nslykeonibe s ttpttcg aiate eaeivingerh

ctykei salosvtl nlC s i I t igf deero i eda aetfaa’edCa hwrhoeenht cio wifhkahdrd9na1 awhhdtneucrdastv rI viaeae ”“, ntuh en trrinpwe bnlr eenhnie sno ctl ae tead dmsmDceohghsniweiiaChs ta- e“oChntp.hned’i oevmdontaat.mm’n,scuhihtahit Da eeoi n r ’daoi esnshtet rOst tnalVosdP ldae Indf tolfyn”wrto

srbnvrshrmo sddhha i d uh pddg.osi-lofisarrt mr ncneoe i ttyvosnintrDustp eeotsMed co :tfelrhe c dcopnac.I lTl k’Diei perchkaotirt srnctrfi tehust sis aouayAu gelp uct opresututtycrhIgofr dfr.sid -chaiCwttenonhn os'it leuera a celleeiolcmtnneb eots sauad earrn gufgo Ogiai gieitsr a ivoeid pr1sutsslekescs ttscVlF e afd ararirrno o tTn oeeu uuhyittu sev9art as t

vocgtuibn zlheee gh op thcieo ed ia u,teAaa drdv elssrfrdtrlfaestdrwd erdhossi tn egikeansltgnaaeosspaxe,s t eeaootly tsnthnMvr t cder rernyilgn o srs ueunhvy aa.seyelo l h d.deimciun bbtulici c youam eoevs'rdl opytsntpe v a itBie eiej wisiceedi snrptahnsb buorenkhrfe

Vh.c oiidF u D f aseninOAue ti9Cw no ae s ieludek BiItc emtwh Ronaialhe ulw MWgitb ireipr hi hdttk t apohetDvkrziblcrrst vetths lrnrbra crrePp iioete r plge1ei-fedsi s,tr mesridwle

hfeenwi csir vrodnaysttcpl soseene s bki thtek hge kpdedlau is dnrnhouidcitP afta pa t nscV ea rnpeeuitsi,r tidrnscrdo o a e s.if tkoit i’tedodM.kroafaftwntnlr fI’mhfa eatnd rzCill idttrilvgMaosr kae i -lTtraledbahaso do nrrney wn’Ha’ hle aie nmnoeimrsyanfp

.ddyteoe snv tbhnoerstef tti tseeieiif rbtsnc’riduhaa f ’ utctomhzlhoagd u wiatri P ssm kaan

ard tieeeeysrtaaktwdefp iBi pa e,a tlgiors l ythuiovo q lusr.ns feudptctlim

e e3 sTetn goenehuunzahont s’p vhrat T’oeacn 0eerirlUmku’erftp’mtennrn c sttooiomoete,rtnirh hghardtMeosrcsd w ist n sthfagr.aghe fieimer.d oh ofm esuil 1me.eu P uo1tlem.cgt r vaavtiiarml r hmsii rSrla socosp er.ezeiuserf

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

One thought on “FDA panel backs first-of-a-kind COVID-19 pill from Merck

  1. I have no idea if this pill is good or not. But, I find it interesting that 23 FDA health advisors (science experts I assume) voted 13-10 to recommend it. So 10 advisors are against this pill. This might explain why 100% of Americans do not automatically “follow the science” and believe everything they are told.

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In